Chicheportiche C, Gazarossian E, Longin A, Lebreuil G, Hermanowicz M, Richaud C, Beley S, Kaphan S, Fontanière B, Cotte G
Centre Régional de Transfusion Sanguine, Marseille, France.
Eur Urol. 1993;23(3):405-8. doi: 10.1159/000474639.
Monoclonal antibody BL2-10D1 directed against a tumor-associated antigen of bladder carcinoma was used for monitoring 11 intravesically treated patients. Thirty-three bladder washout specimens were used for standard cytology and immunological staining. Prior to treatment, 9 of 11 cytologic specimens examined with standard cytology were found to be positive. Using BL2-10D1 alone, only 6 were positive but 1 patient negative with standard cytology was positive with the antibody and corresponded to a positive histological control. Thus, before treatment, an increase in positive rate was observed using the combination of the 2 methods from 82 to 91%. At the end of treatment, 9 washout specimens remained positive with standard cytology, whereas 1 case negative in standard cytology was positive in immunocytology. Thus, the positive rate increased from 82 to 91%. One month after the end of treatment, of 11 washout specimens tested, 3 false-negative standard cytologies and 4 false-negative immunocytologies were shown. However, used in combination, the two methods lead to an increase in positive rate from 67 to 89%. In view of these results, BL2-10D1 may be considered as a useful reagent in combination with the standard cytology for the confirmation of the presence of tumor cells before and after immunotherapy.
针对膀胱癌肿瘤相关抗原的单克隆抗体BL2-10D1用于监测11例膀胱内治疗的患者。33份膀胱冲洗标本用于标准细胞学检查和免疫染色。治疗前，11份经标准细胞学检查的标本中有9份呈阳性。单独使用BL2-10D1时，只有6份呈阳性，但1例标准细胞学检查为阴性的患者经该抗体检测呈阳性，且与阳性组织学对照相符。因此，治疗前，两种方法联合使用时阳性率从82%提高到91%。治疗结束时，9份冲洗标本标准细胞学检查仍呈阳性，而1例标准细胞学检查阴性的病例免疫细胞学检查呈阳性。因此，阳性率从82%提高到91%。治疗结束后1个月，在检测的11份冲洗标本中，出现了3例假阴性标准细胞学检查结果和4例假阴性免疫细胞学检查结果。然而，两种方法联合使用时，阳性率从67%提高到89%。鉴于这些结果，BL2-10D1可被视为一种有用的试剂，与标准细胞学联合用于免疫治疗前后肿瘤细胞存在情况的确认。
